(19)
(11) EP 3 452 514 A1

(12)

(43) Date of publication:
13.03.2019 Bulletin 2019/11

(21) Application number: 17724686.5

(22) Date of filing: 05.05.2017
(51) International Patent Classification (IPC): 
C07K 16/30(2006.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/US2017/031453
(87) International publication number:
WO 2017/193104 (09.11.2017 Gazette 2017/45)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 06.05.2016 US 201662333117 P

(71) Applicant: Fred Hutchinson Cancer Research Center
Seattle, WA 98109 (US)

(72) Inventors:
  • CHAPUIS, Aude
    Seattle WA 98117 (US)
  • GREENBERG, Philip
    Mercer Island WA 98040 (US)
  • SCHMITT, Thomas
    Seattle WA 98107 (US)
  • YEE, Cassian
    Houston TX 77054 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

   


(54) T-CELL IMMUNOTHERAPY SPECIFIC FOR MART-1